Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c, Beats on Revenues; Offers FY17 OpEx Guidance

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.70), $0.13 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $300 thousand.

Financial Guidance

Today the Company provided operating expense guidance for the third quarter and full year 2017. For the third quarter and full year 2017, research and development expenses are expected to be $12.0 to $14.0 million and $46.0 to $51.0 million, respectively, and total operating expenses are expected to be $16.0 to $18.0 million and $63.0 to $68.0 million, respectively.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• NVE Corporation names new CEO and expands board to seven members